are needed including comprehensive neuropsychological assessments and longitudinal investigations. An adaptive or beneficial reorganization must be reflected by behavioural correlates over time. If there is no link between detectable brain changes and any functional outcome, then this may be interpreted as maladaptive compensation lacking any benefit for the patient.
In conclusion, at present, our understanding of cognitive decline in MS is that it most probably occurs as consequence of a network collapse where the preexisting network efficiency gets destroyed by the progressive nature of structural damage. 13 We propose that the time point of clinical manifestation and the extent of measurable deficits are a function of 'adaptive' functional reorganization and not a simple function of the degree of damage.
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Functional reorganization is a maladaptive response to injury -Commentary Menno M Schoonheim
In the multiple sclerosis (MS) community, there has been a lot of debate recently about the concept of functional reorganization, which is commonly defined as the brain's ability to adapt to structural damage. How can we classify whether such functional brain changes are a beneficial or maladaptive response to structural damage? There are two main approaches to measure brain function: the amount of localized activation within brain regions, a reflection of changes in local metabolism triggered by specific tasks, and functional connectivity levels, a reflection of communication between brain regions during a task or at rest. Originally, the concept of functional reorganization was framed around early imaging observations of seemingly beneficial MM Schoonheim increases in connectivity in clinically isolated syndrome 1 and increased activation in cognitively preserved patients, 2 as well as apparently maladaptive decreases in connectivity in progressive MS, 3 and decreased activation in patients with cognitive impairment. 4 If the hypothesis of a beneficial functional reorganization were shown to be true, it could provide new tools to monitor patient functioning and perhaps even identify new targets for future treatment options. Unfortunately, these causal claims on functional plasticity in MS have been difficult to prove. For example, in cognitively impaired MS patients, an increased connectivity at rest was observed, 5 with a concurrent reduction in regional activation. 4 These findings highlight the current consensus that we cannot simply deduce increases in any measure of function as beneficial plasticity and decreases as maladaptive. As such, we need to adopt a more holistic approach that looks at the efficiency of the entire brain network, 6 encompassing both activation and connectivity data, together with measures of structural damage.
Moving towards such a holistic model, however, would also require a renewed, consistent definition of functional reorganization. Rocca and Filippi define functional reorganization as any abnormal activation or connectivity pattern, that is, both adaptive and maladaptive. Conversely, Penner and Aktas define functional reorganization only as an adaptive change in activation, that is, the brain's ability to adapt to brain injury, to counteract functional decline and to overcome disability. Clearly, providing a new definition for functional reorganization may therefore not be so easy, as one must then first decide what separates beneficial from maladaptive, and subsequently which of these changes and techniques are to be included in the definition. Could all forms of functional reorganization actually represent a maladaptive response to injury? Some would argue in favour of this statement (Rocca and Filippi), as the strongest and most extensive changes in both activation and connectivity are seen in patients with clinical deficits and are frequently related to structural damage. Others would argue against (Penner and Aktas), as some increases in activation have been known to correlate positively with clinical scores and only occur in patients with preserved function. But what is the definition of maladaptive functional reorganization? Rocca and Filippi define it as any observation of change in activation or connectivity that is unique to patients with an impaired functional competence, that is, impaired clinical and/ or cognitive functioning. Penner and Aktas, however, define maladaptive changes as any observation where the benefit for the patient is absent, that is, an absence of a correspondence between altered brain function and clinical scores, which is most clearly seen as altered connectivity.
While these definitions of functional reorganization may be practical to work with in the (mostly crosssectional) data that have been published to date, proving this theory is currently impossible. For example, in line with Rocca and Filippi, increases in activation specific to cognitively impaired patients are commonly labelled maladaptive. Unfortunately, it cannot be excluded that these increases might still represent a form of beneficial functional reorganization that is only triggered in later stages of the disease. Additionally, in line with Penner and Aktas, increases in activation that positively correlate with cognitive function are often labelled beneficial. Nonetheless, these seemingly beneficial increases may yet predict a worse cognitive outcome on the longer term, as hyperactivated structures could become overloaded, leaving them at risk for excitotoxicity and neurodegeneration. 7 Therefore, at present, separating good from bad remains impossible, which has led to the strong consensus for a need of longitudinal data with sufficient sample sizes, preferably involving different treatment strategies. 8, 9 Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: M.M.S. receives research support from the Dutch MS Research Foundation, grant number 13-820, and has received compensation for consulting services or speaker honoraria from ExceMed, Genzyme, Novartis and Biogen.
